Literature DB >> 10949029

Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice.

I Shimomura1, M Matsuda, R E Hammer, Y Bashmakov, M S Brown, J L Goldstein.   

Abstract

In mice with too little fat (lipodystrophy) or too much fat (ob/ob), leptin deficiency leads to hyperglycemia, hyperinsulinemia, and insulin resistance. In both disorders, the liver overproduces glucose as a result of resistance to the normal action of insulin in repressing mRNAs for gluconeogenic enzymes. Here we show that chronic hyperinsulinemia downregulates the mRNA for IRS-2, an essential component of the insulin-signaling pathway in liver, thereby producing insulin resistance. Despite IRS-2 deficiency, insulin continues to stimulate production of SREBP-1c, a transcription factor that activates fatty acid synthesis. The combination of insulin resistance (inappropriate gluconeogenesis) and insulin sensitivity (elevated lipogenesis) establishes a vicious cycle that aggravates hyperinsulinemia and insulin resistance in lipodystrophic and ob/ob mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10949029

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  260 in total

Review 1.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.

Authors:  Jay D Horton; Joseph L Goldstein; Michael S Brown
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  From gallstones to genes: two hundred years of sterol research. A tribute to George J. Schroepfer Jr.

Authors:  Geoffrey F Gibbons
Journal:  Lipids       Date:  2002-12       Impact factor: 1.880

Review 3.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

4.  SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation.

Authors:  M Matsuda; B S Korn; R E Hammer; Y A Moon; R Komuro; J D Horton; J L Goldstein; M S Brown; I Shimomura
Journal:  Genes Dev       Date:  2001-05-15       Impact factor: 11.361

5.  PTEN expression causes feedback upregulation of insulin receptor substrate 2.

Authors:  L Simpson; J Li; D Liaw; I Hennessy; J Oliner; F Christians; R Parsons
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

6.  Retinoids induced Pck1 expression and attenuated insulin-mediated suppression of its expression via activation of retinoic acid receptor in primary rat hepatocytes.

Authors:  Yan Zhang; Rui Li; Wei Chen; Yang Li; Guoxun Chen
Journal:  Mol Cell Biochem       Date:  2011-04-26       Impact factor: 3.396

7.  Down-regulation of hepatic HNF4alpha gene expression during hyperinsulinemia via SREBPs.

Authors:  Xuefen Xie; Hailing Liao; Huaixin Dang; Wei Pang; Youfei Guan; Xian Wang; John Y-J Shyy; Yi Zhu; Frances M Sladek
Journal:  Mol Endocrinol       Date:  2009-01-29

Review 8.  Lipid-induced insulin resistance in the liver: role of exercise.

Authors:  Christos S Katsanos
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

9.  ChREBP regulates fructose-induced glucose production independently of insulin signaling.

Authors:  Mi-Sung Kim; Sarah A Krawczyk; Ludivine Doridot; Alan J Fowler; Jennifer X Wang; Sunia A Trauger; Hye-Lim Noh; Hee Joon Kang; John K Meissen; Matthew Blatnik; Jason K Kim; Michelle Lai; Mark A Herman
Journal:  J Clin Invest       Date:  2016-09-26       Impact factor: 14.808

10.  PKClambda in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity.

Authors:  Michihiro Matsumoto; Wataru Ogawa; Kazunori Akimoto; Hiroshi Inoue; Kazuaki Miyake; Kensuke Furukawa; Yoshitake Hayashi; Haruhisa Iguchi; Yasushi Matsuki; Ryuji Hiramatsu; Hitoshi Shimano; Nobuhiro Yamada; Shigeo Ohno; Masato Kasuga; Tetsuo Noda
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.